GET THE APP

..

Transplantation Technologies & Research

ISSN: 2161-0991

Open Access

Atsushi Fujio


Division of Transplantation, Reconstruction, and Endoscopic Surgery, Tohoku University Hospital.

Biography
 ABO-incompatible living donor liver transplantation (ABOi-LDLT) is essential for expanding the donor pool. ABOi-LDLT prognosis has improved since desensitization treatment with rituximab; however, patients with high antibody titers are considered to be at high risk of antibody mediated rejection (AMR). 

Relevant Topics

Google Scholar citation report
Citations: 223

Transplantation Technologies & Research received 223 citations as per Google Scholar report

Transplantation Technologies & Research peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward